Woodline Partners’s Pliant Therapeutics PLRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLRX
TCM
ACM
MAM
LCM
BCM
Woodline Partners's PLRX Position: Q2 2026 in Review
Woodline Partners reduced its Pliant Therapeutics (PLRX) stake by 22% in Q2 2026, selling an estimated $451K and leaving 1,296,534 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #871.
Woodline Partners first reported a position in PLRX in Q3 2020 and has held it in 16 quarters since. The position peaked at $7.56M in Q3 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.
- Woodline Partners held 1,296,534 shares of Pliant Therapeutics worth $1.48M as of Q2 2026.
- Woodline Partners sold 370,296 Pliant Therapeutics shares in Q2 2026, an estimated $451K.
- Pliant Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #871 holding.
- Woodline Partners first reported a position in Pliant Therapeutics in Q3 2020 and has held it in 16 quarters since.
- Woodline Partners's Pliant Therapeutics position peaked at $7.56M in Q3 2023.
- 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.